Member Info for preciousmaj

"The minimum the rights issue needs to raise is £15m for the scheme claimants. On that basis, the 9 billion shares would be offered at 0.1666p. To take part in full, a holder would have to buy 19 of them for each current share. 0.1666p x 19 is just over 3p, which is basically the price of an existing share. So, each holder will have to find approximately the value of the existing portfolio (as it stands this morning) to take part and all of that will be put in the pot for creditors."

Is that decimal point in the right place?
£15m / 9bn shares = 0.00166p
So someone with 1m shares would need an extra £31.5k to buy an additional 19m shares right?

Well done for hanging in there long term holders

Yes Karaleva, that's correct

Could I urge all Omega shareholders to sign up to the Omega Shareholder Action Group? The objective of the group is to force CK out. Sentiment is at rock bottom due to his poor leadership. The market has lost trust in him, we need a good communicator and leader to move the company forward.

Please email the following information to osag at mail.com:
Full Name, City, County, No of shares held and Mobile Number

Personal info will be kept private & confidential. I have no interest in this information, this will be needed for UK Shareholders Association to verify holdings once we hit the holding threshold.

Shareholders who represent +5% of the company can requisition an EGM. We need at least 9.1m shares to arrange this.

Shareholders are rightly pinning hopes on home use approval (HUA) but CK still needs removing as the CEO as market has no confidence in him. He is out of his depth and needs to be removed immediately, his replacement needs to bring some fresh ideas and excitement back to Omega.

The self-test approval needs to come first then CTDA to follow this announcement. There are high hopes for this and I'm expecting HUA but if this is NOT granted then do you expect CK to inform shareholders considering his poor track record?

Omega were relying on the Mologic AG test to pass Porton Down, CK pinned all his hopes on this LFT but did not inform the market when it failed to get approval. Also the poor comms from the company and comments like “after the elections”, “transformational year”, “imminently” and “this is literally the only picture Colin would sign off” created unnecessary hype that led to shareholders buying more shares.

Thank you to those who have joined already via Twitter call late last week. The response has been fantastic. Some of the conversations that I’ve had with shareholders have been interesting, clearly CK favours some shareholders over others. We're still short of the threshold needed and would appreciate shareholders join the fight to remove CK and collectively send a clear message to the Board.

Once the resolution is on the table and EGM is called, you would expect the majority of shareholders to vote this incompetent CEO out. Just a threat of getting voted out should get him removed.

I am a member of the UK Shareholders Association and have been involved in a couple of action groups with them already.

Follow on Twitter for more information as posts are getting removed on LSE. Some clearly don't like the suggestion of CK's removal.

''Spoken with Colin directly on a number of occasions and I have faith in his ability''

There lies the issue, I have been emailing him for over a year and he hasn't responsed to me once. There has been no abuse from me. I have offered to speak to him over the phone. CK responds to some but not others, certainly has his favourites from the comms I've had with other shareholders. FYI I have substantially more than £200 invested :-)

BIGBangs, follow me on Twitter and see what work I have done already with other action groups. Send me a DM if you want to talk privately. There has been a positive response to the action group, we're well on our way to getting the required 9.1m shares that are needed. Further details will be provided to OSAG members only.

BIGBangs, you have questioned the requirement of 5% Omega shareholding may be too great but the OSAG is making great progress. The group was set up a few days ago and response has been fantastic so far, come on board.

https://twitter.com/AIMissionary/status/1466410312425525260?s=20

BIGBangs, follow me on Twitter and see what work I have done already with other action groups. Send me a DM if you want to talk privately. I have better things to be doing then collecting personal data from the ODX BB. I am a Director of a manufacturing company and ODX is not my biggest investment FYI. I am taking this action to protect my investment.

No funds are required.

I am a member of the UK Shareholders Association and have been involved in a couple of action groups with them already.

I have checked with Omega and 5% of shareholders can call an EGM.

Those complaining about me not posting on this bb are getting my posts removed, maybe this is the reason I haven't posted on the bb regularly. You can see my posts over the summer and on Twitter.

I have been invested since April 2020.

You can see the original post on Twitter:
https://twitter.com/AIMissionary/status/1467794135952371716?s=20

Thank you to those who have emailed details.

All long term holders need to join the action group.

My comments are getting removed by this mob, some clearly doesn't like the suggestion of CK's removal.

I liaised with Omega and 5% of shareholders can call an EGM.

Who is getting my posts removed and why?

I presume the share price will continue to drift until we get a further update in relation to Federated Wireless IPO or another funding round. It would be nice to have an actual timeline from the ALM Board without giving sensitive information away or is that too much to ask for? Something like we need to tick these boxes before FW can list would be sufficient.

Disappointed to learn of the 12.8% Fully-Diluted interest in OcuTerra Therapeutics but probably for the best as ALM Board wants to wind down holdings. Post-Money Valuation is $49.5 million and our interest is valued at around $6.3m now.

We don't know the details and should have had an RNS advising of the fund raise.

If there was dilution to our holding or if ALM participated in the fund raise we should be told via RNS.

As you can see below OcuTerra has raised a further $35m in addition to the $14.6m it secued earlier this year. This bodes extremely well for our 54.16% holding in the company.

“OTT166 offers potential significant benefit for patients, caregivers and eye care practitioners by providing a non-invasive treatment option for people suffering from diabetic retinopathy,” said Carl Regillo, M.D., FACS, Chief of the Retina Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University. “In addition to fulfilling the unmet need of offering a non-invasive treatment option, which would be acceptable to more patients, OTT166 can potentially be administered earlier than eye injections, which may prevent severe disease progression and functional vision loss. I am compelled by the early data and believe that OTT166 has the potential to transform the standard of care for patients with this disease.”

OcuTerra Expands Scientific Advisory Board

OcuTerra also announced the appointment of Paul M. Karpecki, OD, FAAO to its Scientific Advisory Board.

“We are delighted to have Dr. Karpecki join our Scientific Advisory Board as we move forward with the development of OTT166,” said David Tanzer, M.D., ophthalmologist and Chief Medical Officer of OcuTerra. “Paul is a leader and pioneer in the eye care field, and his commitment to innovation aligns with our mission to change the standard of care for the treatment of diabetic eye disease.”

“I am thrilled to join the Scientific Advisory Board of OcuTerra and represent the voice of Doctors of Optometry who manage over 70% of all patients with diabetic retinopathy in the U.S.,” said Dr. Karpecki. “Working closely with my fellow advisors from the retina and anterior segment ophthalmology communities, I am very excited about the development of OTT166, a topical drug candidate to prevent diabetic retinopathy disease progression and loss of visual function.”

Dr. Karpecki received his Doctor of Optometry degree from Indiana University and completed a Durrie Fellowship in Medical Cornea/Refractive Surgery in Kansas City in affiliation with the Pennsylvania College of Optometry. In 2017-2018 he completed a full year preceptorship in advanced retinal disease at Retina Associates of Kentucky, one of the top 20 retina practices in the country. He currently serves as Director of Cornea and External Disease for the Kentucky Eye Institute in Lexington KY. Dr. Karpecki is the Chief Clinical Editor for Review of Optometry, the most read journal in the profession, and chairman of the New Technology and Treatment Conferences. He is Medical Director for KEPLR Vision and Director of Cornea and External Disease for the Center for Sight in Carmel, IN. He was appointed to the Delphi International Society at Wilmer Johns Hopkins which included the top 25 dry eye experts in the world and co-chair for the previous two Tear Film and Ocular Surface Society Symposia. Dr. Karpecki served on the DEWS II Diagnostic Methodology Committee. He is also an Associate Professor at the Kentucky College of Optometry in Pikeville, KY and serves on the board of the charitable organization Optometry

OcuTerra Raises $35 Million Series B Financing

OTT166 DR-EAM Phase 2 Study Expected to Commence Early 2022

Paul Karpecki, OD, FAAO, Appointed to Scientific Advisory Board

November 09, 2021 06:00 AM Eastern Standard Time

BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch and wait” does not prevent or control the progression of disease, today announced the final close of a $35 million Series B financing. Proceeds will support the DR-EAM (Diabetic Retinopathy - Early Active Management) Phase 2 study of OTT166 in patients with moderate to severe non-proliferative and mild proliferative diabetic retinopathy. The study is expected to commence early next year.

Phase 1b clinical trials of OTT166 eye drops in patients with diabetic retinopathy and wet AMD have demonstrated safety, tolerability and clear clinical evidence of biological activity. OTT166 is a novel small molecule selective integrin inhibitor that OcuTerra has purpose engineered to have the required physiochemical characteristics to be able to reach the retina from eye drop application. Designed to be administered by the patient at home, OTT166 has the potential to dramatically change the treatment paradigm by enabling earlier, non-invasive treatment to preserve vision and prevent progression, thereby delaying or completely eliminating the need for intravitreal injections.

“OcuTerra is well-positioned to transform the treatment landscape for diabetic retinopathy, the leading cause of vision loss and blindness in working age adults in America,” said Kerrie Brady, Chief Executive Officer of OcuTerra. “The current standard of care for these patients is ‘watch and wait’ until vision deteriorates due to diabetic macular edema or the disease progresses to the proliferative form, at which point medically intensive and invasive eye injections and/or laser treatments are instituted. Our mission is to transform the standard of care with OTT166 to offer a non-invasive, easy to administer, effective treatment that can be prescribed earlier in the disease course by a broader range of eye care providers to avoid sight threatening complications, stop disease progression and potentially avoid invasive treatments. We look forward to evaluating OTT166 in Phase 2 trials beginning early next year.”

CONT...

Yes Echo1, Federated Wireless has great potential. I don't think ALM will be able to mess the listing up, Harry Rein sits on the Board along with 7 other very capable individuals. I've got a lot of time for CEO Iyad Tarazi too. FW has 8 very capable investors who would want the highest return they can achieve. If they wanted to make life easier for themselves, they could probably flog the company to the likes of Amazon / Google now for profit or they could wait some time to sell for multiples.

HigherRating, I think ST was basing his opinion on the research note from Edison. Spin Memory was valued at $180m, ALM fully diluted share was being valued at $60m+. Luckily for ALM shareholders, the company is diversified and we could still make decent returns from the likes of FW. Its also worth noting that OcuTerra Therapeutics was given a ZERO valuation previously but secured $14.6m in funding earlier this year, ALM have a 54.16% holding in the company.

It feels to me Federated Wireless are getting ready for an IPO, Simon Thompson was talking of this a few months back and predicted an $1bn+ valuation.

Allied Minds ownership is 43.11% and fully-diluted ownership is 36.61%.

The SP should be 100p+ just based on the above, even if FW have a $500m valuation the SP should be more than double the current price. I think investor appetite is low due to past board performance but the market will be surprised when the company is listed IMO.

Long History of Market Leadership
The CBRS market leader, Federated Wireless was the first to launch a commercial spectrum access system (SAS) and environmental sensing capability (ESC) network, which have been deployed across several vertical markets with numerous use cases. The company currently has more than 200 customers with 70k+ connected devices across the United States and overseas. Its customer base includes electric co-ops; large interstate gas and electric; oil refineries; commercial and federal enterprises, and tier one Mobile Network Operators (MNOs), including Verizon Wireless nationwide CBRS 4G and 5G. Additional deployments include tier one cable operators and tower companies; and more than 100 Wireless Internet Service Providers (WISPs).

"The last 12 months have seen strong growth in interest, traction and innovation from Federated Wireless, the FCC and other players in the market as we work together to build what promises to be the single most significant contributor to US 5G leadership," said Tarazi. "I would like to thank our customers, our partners and our investors as we head into what promises to be another record-shattering year for CBRS, shared spectrum and private 5G."

2/2